US Clinical Trial NCT03951623

The Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMPL-523, a Syk Inhibitor in Adult Patients of Immune Thrombocytopenia: a Randomized, Double Blinded, Placebo Controlled Phase Ib Study  May 14, 2019

Approximate 51 to 60 patients will be enrolled in dose escalation (3 cohorts, 8 subjects each with the ratio of 3:1 vs Placebo) and dose expansion (1 cohort, 27-36 subjects with the ratio of 2:1 vs Placebo).

Parties

Contacts
Investigators
Sponsors
Countries
CN
Keywords
ITP Immune Thrombocytopenia (ITP) syk inhibitor

JSON preview

Similar records

Title

Source:  NIH Last updated:  Jun 12, 2019

From ClinicalTrials.gov, a database of the U.S. National Institutes of Health, through its National Library of Medicine. This record may not reflect the most current and accurate biomedical/scientific data available from the NLM/NIH.